L3VLUP
ProSign in

ILMN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ILMNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ILMN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterILMNVRTX
Q3 202019 holders, $9.2bn31 holders, $21.9bn
Q4 202022 holders, $11.9bn30 holders, $18.4bn
Q1 202127 holders, $13.7bn31 holders, $15.4bn
Q2 202123 holders, $16.3bn30 holders, $12.7bn
Q3 202131 holders, $14.7bn35 holders, $10.1bn
Q4 202122 holders, $13.3bn28 holders, $12.4bn
Q1 202220 holders, $12.1bn23 holders, $16.1bn
Q2 202221 holders, $6.3bn25 holders, $18.1bn
Q3 202218 holders, $7.3bn22 holders, $18.4bn
Q4 202213 holders, $7.7bn28 holders, $18.4bn
Q1 202322 holders, $8.9bn26 holders, $21.4bn
Q2 202315 holders, $6.8bn27 holders, $24.7bn
Q3 202314 holders, $4.6bn33 holders, $24.3bn
Q4 202321 holders, $3.6bn32 holders, $28.6bn
Q1 202416 holders, $3.4bn31 holders, $29.8bn
Q2 202422 holders, $2.3bn29 holders, $33.4bn
Q3 202422 holders, $2.9bn27 holders, $33.5bn
Q4 202416 holders, $4.1bn26 holders, $28.5bn
Q1 202511 holders, $2.3bn21 holders, $35.4bn
Q2 20258 holders, $2.5bn21 holders, $32.3bn
Q3 20259 holders, $2.9bn22 holders, $25.9bn
Q4 202510 holders, $4.6bn26 holders, $31.8bn
Q1 202613 holders, $3.9bn25 holders, $31.8bn
Q2 202613 holders, $5.9bn26 holders, $34.6bn
ILMN

Illumina Inc

Holders
21
Reported value
$3.6bn
Buyers
12
Sellers
9

Breadth +3 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ILMN (8)

Baillie Gifford & Co, Carl C. Icahn, Coatue Management LLC, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Polen Capital Management LLC, Soros Fund Management LLC, ValueAct Holdings LP

Only VRTX (19)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Farallon Capital Management LLC, Fidelity (FMR LLC), Man Group PLC, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →